Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis

Mayo Clinic Proceedings

Volumn 86, Issue 6, 2011, Pages 480-488

  Mckinnell, James A ^a,b   Stollenwerk, Nicholas S ^c   Jung, Chin W ^d   Miller, Loren G ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TORRANCE MEMORIAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KAISER PERMANENTE   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; NITROFURANTOIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DECISION TREE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG THERAPY; EMPIRICAL TREATMENT; ESCHERICHIA COLI INFECTION; FEMALE; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; SYSTEMATIC REVIEW; UNCOMPLICATED URINARY TRACT INFECTION; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI;

EID: 79957756361     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0800     Document Type: Article

References (59)

1. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel J. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10:509-515.
2. Johnson JR, Stamm W. Diagnosis and treatment of acute urinary tract infections [published correction appears in Infect Dis Clin North Am.1990;4(2):following xii] Infect Dis Clin North Am. 1987;1(4):773-791.
3. Gupta K, Scholes D, Stamm W. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999;281:736-738. (Pubitemid 29113455)
4. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother. 2002;46(8):2540-2545. (Pubitemid 34793461)
5. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother. 2003;51:69-76. (Pubitemid 36163829)
6. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103-e120.
7. Spencer RC, Moseley DJ, Greensmith MJ. Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice. J Antimicrob Chemother. 1994;33(suppl A):121-129. (Pubitemid 24201990)
8. Gupta K, Hooton T, Roberts P, Stamm W. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med. 2007;167:2207-2212. (Pubitemid 350106740)
9. 2010 Red Book: Pharmacy's Fundamental Reference. 114th ed. New York, NY: Thomson Reuters (Healthcare); 2010.
10. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis. 2001;33:615-621.
11. Perfetto EM, Gondek K. Escherichia coli resistance in uncomplicated urinary tract infection: a model for determining when to change first-line empirical antibiotic choice. Manag Care Interface. 2002;15:35-42. (Pubitemid 34694687)
12. Perfetto EM, Keating K, Merchant S, Nichols BR. Acute uncomplicated UTI and E. coli resistance: implications for first-line empirical antibiotic therapy. J Manag Care Pharm. 2004;10:17-25.
13. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE; Infectious Diseases Society of America (IDSA). Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 1999;29:745-758.
14. Anderson RU. Management of lower urinary tract infections and cystitis. Urol Clin North Am. 1999;26:729-735. (Pubitemid 29498561)
15. Hooton TM. Practice guidelines for urinary tract infection in the era of managed care. Int J Antimicrob Agents. 1999;11:241-245. (Pubitemid 29231968)
16. Hooton TM. Pathogenesis of urinary tract infections: an update. J Antimicrob Chemother. 2000;46(suppl 1):1-7.
17. Carlson KJ, Mulley AG. Management of acute dysuria: a decision-analysis model of alternative strategies. Ann Intern Med. 1985;102:244-249.
18. Iravani A. Advances in the understanding and treatment of urinary tract infections in young women. Urology. 1991;37:503-511.
19. Echols RM, Tosiello RL, Haverstock DC, Tice AD. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis. 1999;29:113-119. (Pubitemid 29336812)
20. Johnson JR, Stamm WE. Urinary tract infections in women: diagnosis and treatment. Ann Intern Med. 1989;111(11):906-917. (Pubitemid 20000026)
21. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for the antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 1999;29:745-758. (Pubitemid 30256361)
22. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract. 1997;44:49-60. (Pubitemid 27049710)
23. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999;21(11):1864-1872.
24. Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother. 1999;43(suppl A):67-75. (Pubitemid 29123504)
25. Henry DC Jr, Bettis RB, Riffer E, et al. Comparison of once-daily extended- release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther. 2002;24:2088-2103.
26. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis. 2001;33:615-621.
27. Talan DA, Naber KG, Palou J, Elkharrat D. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. Int J Antimicrob Agents. 2004;23S1:S54-S66. (Pubitemid 38376050)
28. Kallen AJ, Welch HG, Sirovich BE. Current antibiotic therapy for isolated urinary tract infections in women. Arch Intern Med. 2006;166:635-639.
29. 2007 Red Book: Pharmacy's Fundamental Reference. 111th ed. Fleming T, ed. Montvale, NJ: Medical Economics Company; 2007.
30. AHA Hospital Statistics. 2007 edition. Chicago, IL: American Hospital Association; 2007.
31. Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA. 1995;273:41-45.
32. Neuner JM, Hamel MB, Phillips RS, Bona K, Aronson MD. Diagnosis and management of adults with pharyngitis: a cost-effectiveness analysis. Ann Intern Med. 2003;139:113-122. (Pubitemid 38129103)
33. Rubin N, Foxman B. The cost-effectiveness of placing urinary tract infection treatment over the counter. J Clin Epidemiol. 1996;49:1315-1321. (Pubitemid 26386236)
34. Centers for Medicare and Medicaid Services. US Department of Health and Human Services Web site. http://www.cms.gov/. Accessed February 23, 2011.
35. Coley AL, Todd MW, Harrington P. Treatment of serious urinary tract infections at a university teaching hospital: a retrospective chart review. Hosp Formul. 1990;25(5):548-552. (Pubitemid 20205609)
36. Bailey RR, Lynn KL, Robson RA, Peddie BA, Smith A. Comparison of ciprofloxacin and netilmicin for the treatment of acute pyelonephritis. N Z Med J. 1992;105(930):102-103.
37. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA. 2000;283(12):1583-1590. (Pubitemid 30161514)
38. Takahashi S, Hirose T, Satoh T, et al. Efficacy of a 14-day course of oral ciprofloxacin therapy for acute uncomplicated pyelonephritis. J Infect Chemother. 2001;7:255-257. (Pubitemid 34101077)
39. AHA Hospital Statistics. 2010 edition. Chicago, IL: American Hospital Association; 2010.
40. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis. 2002;34(8):1061-1066. (Pubitemid 34289678)
41. Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim- sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections in a geographical area with a high prevalence of TMP-SMXresistant uropathogens. Clin Infect Dis. 2002;34:1165-1169. (Pubitemid 34450662)
42. Engel JD, Schaeffer AJ. Evaluation of and antimicrobial therapy for recurrent urinary tract infections in women. Urol Clin North Am. 1998;25:685-701. (Pubitemid 28514171)
43. Rosenberg M. Pharmacoeconomics of treating uncomplicated urinary tract infections. Int J Antimicrob Agents. 1999;11:247-251. (Pubitemid 29231969)
44. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract. 1997;44(1):49-60. (Pubitemid 27049710)
45. Henry NK, Schultz HJ, Grubbs NC, Muller SM, Ilstrup DM, Wilson WR. Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women. J Antimicrob Chemother. 1986;18(suppl D):103-106. (Pubitemid 17214199)
46. Henry DC, Nenad RC, Iravani A, et al. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Clin Ther. 1999;21(6):966-981. (Pubitemid 29326157)
47. Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer J. Randomized controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract. 2002;52(482):729-734. (Pubitemid 36187595)
48. McCarty JM, Richard G, Huck W, et al. A randomized trial of shortcourse ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Am J Med. 1999;106:292-299. (Pubitemid 29153406)
49. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidasis. N Engl J Med. 2004;351:876-883.
50. Miller LG, Tang AW. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin Proc. 2004;79(8):1048-1053.
51. Norrby SR, Nord CE, Finch R; European Society of Clinical Microbiology and Infectious Diseases. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis. 2005;5(2):115-119.
52. McDonald LC, Chen FJ, Lo HJ, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother. 2001;45(11):3084-3091. (Pubitemid 32988832)
53. Cizman M, Orazem A, Krizan-Hergouth V, Kolman J. Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections [letter]. J Antimicrob Chemother. 2001;47:502. (Pubitemid 32303427)
54. Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2006;27:468-475.
55. Arslan H, Azap O, Ergonul O, Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community- acquired urinary tract infections in Turkey. J Antimicrob Chemother. 2005;56:914-918. (Pubitemid 41631917)
56. Astal ZE. Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in the Gaza Strip. Singapore Med J. 2005;46(9):457-460. (Pubitemid 41248291)
57. Johnson L, Sabel A, Burman WJ, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med. 2008;121:876-884.
58. Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother. 2006;50:2251-2254. (Pubitemid 43807558)
59. Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract. 2002;52:729-734. (Pubitemid 36187595)